Publication:


abstract

PURPOSE:

the purpose of this preclinical study was to determine the effectiveness of RAF265, a multikinase inhibitor, for treatment of Human metastatic Melanoma and to characterize traits associated with drug response.

EXPERIMENTAL DESIGN:

Advanced metastatic melanoma Tumors from 34 patients were orthotopically implanted to nude mice. Tumors that grew in mice (17 of 34) were evaluated for response to RAF265 (40 mg/kg, every day) over 30 days. The relation between patient characteristics, gene mutation profile, global gene expression profile, and RAF265 effects on tumor Growth, mitogen-activated protein/extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK) phosphorylation, proliferation, and apoptosis markers was evaluated.

RESULTS:

Nine of the 17 tumors that successfully implanted (53%) were mutant BRAF (BRAF(V600E/K)), whereas eight of 17 (47%) tumors were BRAF wild type (BRAF(WT)). Tumor implants from 7 of 17 patients (41%) responded to RAF265 treatment with more than 50% reduction in tumor growth. Five of the 7 (71%) responders were BRAF(WT), of which 1 carried c-KIT(L576P) and another N-RAS(Q61R) mutation, while only 2 (29%) of the responding tumors were BRAF(V600E/K). Gene expression microarray data from nonimplanted tumors revealed that responders exhibited enriched expression of genes involved in cell growth, proliferation, development, cell signaling, gene expression, and cancer pathways. Although response to RAF265 did not correlate with pERK1/2 reduction, RAF265 responders did exhibit reduced pMEK1, reduced proliferation based upon reduced Ki-67, cyclin D1 and polo-like kinase1 levels, and induction of the apoptosis mediator BCL2-like 11.

CONCLUSIONS:

Orthotopic implants of patient tumors in mice may predict prognosis and treatment response for melanoma patients. A subpopulation of human melanoma tumors responds to RAF265 and can be characterized by gene mutation and gene expression profiles. Clin Cancer Res; 18(8); 2184-98. ©2012 AACR.

Related Articles
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Proc Natl Acad Sci U S A. 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, et al. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14903-8. Epub 2010 Jul 28.
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Cancer Res. 2011
Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J, Shen Q, Labow M, Gaither LA. Cancer Res. 2011 Jun 15; 71(12):4280-91. Epub 2011 Apr 28.
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
J Clin Endocrinol Metab. 2007
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD. J Clin Endocrinol Metab. 2007 Dec; 92(12):4712-8. Epub 2007 Sep 18.
Review Therapeutic strategies for targeting BRAF in human cancer.
Rev Recent Clin Trials. 2007
Review Therapeutic strategies for targeting BRAF in human cancer.
Pratilas CA, Solit DB. Rev Recent Clin Trials. 2007 May; 2(2):121-34.
Review Mouse models for BRAF-induced cancers.
Biochem Soc Trans. 2007
Review Mouse models for BRAF-induced cancers.
Pritchard C, Carragher L, Aldridge V, Giblett S, Jin H, Foster C, Andreadi C, Kamata T. Biochem Soc Trans. 2007 Nov; 35(Pt 5):1329-33.